

Are your MRI contrast agents cost-effective?

Learn more about generic Gadolinium-Based Contrast Agents.



**AJNR**

**The Role of Amyloid- $\beta$ , tau, and  
*Apolipoprotein E*  $\epsilon$ 4 in Alzheimer Disease:  
How Is the Team Playing?**

M. Filippi, E. Canu and F. Agosta

*AJNR Am J Neuroradiol* published online 23 August 2012  
<http://www.ajnr.org/content/early/2012/08/23/ajnr.A3295.citation>

This information is current as of April 19, 2024.

## COMMENTARY

## The Role of Amyloid- $\beta$ , tau, and Apolipoprotein E $\epsilon 4$ in Alzheimer Disease: How Is the Team Playing?

The distinctive histopathologic hallmarks of Alzheimer disease (AD) are the neuritic plaques and the neurofibrillary tangles (NFT). Albeit described for the first time by Alois Alzheimer in 1907, the relationship of these histologic abnormalities to the pathogenesis of AD is still unclear.

An elevated CSF tau level is considered an in vivo marker of NFT, and a low CSF amyloid- $\beta_{1-42}$  ( $A\beta_{1-42}$ ) level as a marker of  $A\beta$  plaque deposition in the brain of patients with AD.<sup>1</sup>  $A\beta$  deposition is believed to initiate a process that subsequently leads to a loss of dendrites, synapses, and cells. However,  $A\beta$  plaques can also be detected in cognitively healthy elderly, their presence is only weakly associated with cognitive decline in both healthy individuals and patients with AD, and their removal does not prevent the occurrence of other neurodegenerative processes.<sup>1</sup> These findings suggest that once the downstream process is triggered by  $A\beta$  deposition, other factors play a role in giving rise to the complete clinical/pathologic picture of AD.

In the article by Desikan et al published in this issue, the authors have investigated the interaction of CSF  $A\beta_{1-42}$ , CSF phospho-tau (p-tau), and Apolipoprotein E  $\epsilon 4$  (*ApoE*  $\epsilon 4$ ; the current major genetic risk factor for AD) on the rate of tissue loss of the entorhinal cortex and other AD-vulnerable cortical regions in cognitively healthy elderly enrolled in the longitudinal Alzheimer Disease Neuroimaging Initiative (<http://www.adni-info.org/Home.aspx>). No effect of CSF  $A\beta_{1-42}$ , p-tau, and *ApoE*  $\epsilon 4$  were observed on the rate of cortical tissue loss, thus suggesting that none of the investigated biomarkers taken in isolation can provide an accurate account of the pathologic processes occurring in preclinical AD. Conversely, they have observed a significant interaction of CSF  $A\beta_{1-42}$  and CSF p-tau on cortical volume loss with time, as previously reported by the same group in both healthy individuals and patients with mild cognitive impairment.<sup>2</sup> The novel piece of information is that though the presence of the  $\epsilon 4$  allele correlates with CSF  $A\beta_{1-42}$  levels, there is no interaction between *ApoE*  $\epsilon 4$  and CSF  $A\beta_{1-42}$  or p-tau on cortical tissue loss. This finding allowed the authors to conclude that *ApoE*  $\epsilon 4$  may have a role in modulating preclinical AD pathology via  $A\beta$ -related mechanisms but that  $A\beta$ -associated neurodegenerative processes occur only in the presence of p-tau. This longitudinal study is important because its results improve our knowledge on AD pathophysiology, but it leaves open some questions on the pathologic mechanisms underlying this complex disease.

Concerning the temporal sequence of events, it is known that in the preclinical phase of AD, CSF  $A\beta$  correlates with structural brain abnormalities, while in mild AD, CSF tau, but not  $A\beta$ , is associated with the extent of brain atrophy.<sup>1</sup> However, the role of tau in the preclinical stage of AD and its influence on cortical tissue loss are still controversial. In this context, a recent study failed to detect a relationship between levels of CSF tau and the extent of cortical volume loss in healthy individuals at risk of developing AD.<sup>3</sup> On the other

hand, these authors showed an association between CSF tau and white matter microstructural abnormalities (assessed by using diffusion tensor MR imaging) of regions adjacent to cortical areas known to be frequently affected by the disease.<sup>3</sup> This suggests that injury to cerebral tissues other than the cortex should be considered when integrating AD biomarkers.<sup>3-5</sup>

The *ApoE*  $\epsilon 4$  allele has been found to correlate strongly with CSF  $A\beta$  levels in the preclinical phase of AD.<sup>6</sup> On the other hand, in patients with overt cognitive decline such a relationship is weaker, leading to the hypothesis that in  $\epsilon 4$  carriers,  $A\beta$  deposition may reach a plateau before the neurodegenerative aspects of the disease are fully expressed.<sup>6</sup> What we know today is that *ApoE*  $\epsilon 4$  likely predates the onset of  $A\beta$  deposition.<sup>6</sup> However, *ApoE*  $\epsilon 4$  may also act independently of the  $A\beta$  peptide through a dysregulation of tau phosphorylation, disruption of the cytoskeletal structure, and mitochondrial damage.<sup>7</sup> As a consequence, future studies are warranted to clarify the different molecular mechanisms underlying the role of *ApoE*  $\epsilon 4$  in preclinical stages of AD.

To conclude, the identification of AD biomarkers would represent an important step forward in the understanding of the pathophysiology of this condition. Recent multicenter and longitudinal studies are shedding light on the mechanisms and their interactions that then result in the clinical/pathologic picture of AD. These studies are making clear that the question "How is the team playing?" is more important than the one asking, "Who is playing first base?" and that the combination of MR imaging, CSF, and genetic data, describing in the best possible way the AD preclinical stages, is likely to contribute to the identification of a constellation of AD biomarkers, which may be useful for an early diagnosis, monitoring of disease progression, and assessing treatment efficacy once disease-modifying drugs become available.

### References

1. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol* 2010;9:119-28
2. Desikan RS, McEvoy LK, Thompson WK, et al. Amyloid-beta associated volume loss occurs only in the presence of phospho-tau. *Ann Neurol* 2011;70:657-61
3. Bendlin BB, Carlsson CM, Johnson SC, et al. CSF T-tau/Abeta(42) predicts white matter microstructure in healthy adults at risk for Alzheimer's disease. *PLoS One* 2012;7:e37720
4. Agosta F, Pievani M, Sala S, et al. White matter damage in Alzheimer disease and its relationship to gray matter atrophy. *Radiology* 2011;258:853-63
5. Canu E, Frisoni GB, Agosta F, et al. Early and late onset Alzheimer's disease patients have distinct patterns of white matter damage. *Neurobiol Aging* 2012; 33:1023-33
6. Vemuri P, Wiste HJ, Weigand SD, et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. *Ann Neurol* 2010;67:308-16
7. Agosta F, Vessel KA, Miller BL, et al. Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. *Proc Natl Acad Sci U S A* 2009;106:2018-22

M. Filippi

Neuroimaging Research Unit

Institute of Experimental Neurology, Division of Neuroscience

Department of Neurology

E. Canu

F. Agosta

Neuroimaging Research Unit

Institute of Experimental Neurology, Division of Neuroscience

San Raffaele Scientific Institute

Vita-Salute San Raffaele University

Milan, Italy

<http://dx.doi.org/10.3174/ajnr.A3295>